Table 3.
Pyrotinib-related AEs of all grades and grade 3–4.
| Pyrotinib dose 320 mg daily (n = 15) | Pyrotinib dose 400 mg daily (n = 153) | Total (n = 168) | ||||
|---|---|---|---|---|---|---|
| AE | All grade | Grade 3–4 | All grade | Grade 3–4 | All grade | Grade 3–4 |
| Diarrhea | 14 (93.0%) | 3 (20.0%) | 151 (98.7%) | 31 (20.2%) | 165 (98.2%) | 33 (19.6%) |
| Nausea & vomiting | 8 (53.3%) | 1 (6.7%) | 76 (49.7%) | 12 (7.8%) | 84 (50.0%) | 13 (7.7%) |
| Leukopenia | 7 (46.7%) | 1 (6.7%) | 75 (49.0%) | 12 (7.8%) | 82 (48.8%) | 13 (7.7%) |
| Decreased appetite | 6 (40%) | 54 (35.3%) | 4 (2.6%) | 60 (35.7%) | 4 (2.4%) | |
| Hand-foot syndrome | 4 (26.7%) | 1 (6.7%) | 43 (28.1) | 10 (6.5%) | 47 (28.0%) | 11 (6.5%) |
| Asthenia | 4 (26.7%) | 28 (18.3%) | 32 (19%) | |||
| Oral ulceration | 2 (13.3%) | 17 (11.1%) | 3 (2%) | 19 (11.3%) | 3 (1.8%) | |
| Rash | 1 (6.7%) | 13 (8.5%) | 14 (8.3%) | |||
| Dizziness | 0 (0%) | 9 (5.9%) | 9 (5.4%) | |||
| Muscle spasms | 1 (6.7%) | 5 (3.4%) | 6 (3.6%) | |||
| Paronychia | 1 (6.7%) | 5 (3.3%) | 2 (1.3%) | 6 (3.6%) | 2 (1.2%) | |
| Cough | 2 (13.3%) | 4 (2.6%) | 6 (3.6%) | |||
| Haematochezia | 0 (0%) | 3 (2%) | 3 (1.8%) | |||
| Abdominal Pain | 0 (0%) | 3 (2%) | 3 (1.8%) | |||
| Oedema | 0 (0%) | 3 (2%) | 3 (1.8%) | |||
| Epistaxis | 1 (6.7%) | 1 (0.7%) | 2 (1.2%) | |||
Pyrotinib-related adverse events (AEs) includes definitely related AEs and probably related AEs.